Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan in Rett Syndrome
NCT00593957Phase 2Terminated
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger
- Start
- Aug 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dextromethorphan in Rett syndrome (RTT) (3 arms), sponsored by Hugo W. Moser Research Institute at Kennedy Krieger. Primary endpoint: Difference in EEG Spike Counts at Six Months Compared to Baseline at 6 months. Started Aug 2004; status: terminated.
02
Drugs
dextromethorphan
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT00593957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593957.